Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Studies have attempted to demonstrate the benefits of silicon on bone health using a wide range of Si amounts-provided in the diet or through supplementation-and several different animal species. Previous studies in humans have also demonstrated a positive correlation between Si intake and bone health measures. The aim of the current review is to determine the effective levels of Si intake or supplementation that influence bone health to better inform future study designs and guidelines. Articles were identified using one of two search terms: "silicon AND bone" or "sodium zeolite A AND bone". Articles were included if the article was a controlled research study on the effect of Si on bone health and/or mineral metabolism and was in English. Articles were excluded if the article included human subjects, was in vitro, or studied silica grafts for bone injuries. Silicon type, group name, Si intake from diet, Si supplementation amount, animal, and age at the start were extracted when available. Dietary Si intake, Si supplementation amount, and the amount of Si standardized on a kg BW basis were calculated and presented as overall mean ± standard deviations, medians, minimums, and maximums. Studies that left out animal weights, amount of food or water consumed, or nutrient profiles of the basal diet were excluded from these calculations. Standardized Si intakes ranged from 0.003 to 863 mg/kg BW, at times vastly exceeding current human Si intake recommendations (25 mg/d). The lack of data provided by the literature made definitively determining an effective threshold of supplementation for skeletal health difficult. However, it appears that Si consistently positively influences bone and mineral metabolism by around 139 mg Si/kg BW/d, which is likely unfeasible to attain in humans and large animal species. Future studies should examine this proposed threshold more directly and standardize supplemental or dietary Si intakes to kg BW for better study replication and translation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10857027PMC
http://dx.doi.org/10.3390/nu16030339DOI Listing

Publication Analysis

Top Keywords

bone health
20
animal species
8
intake supplementation
8
mineral metabolism
8
supplementation amount
8
bone
7
health
6
intake
5
silicon supplementation
4
supplementation bone
4

Similar Publications

Background: Blinatumomab and inotuzumab ozogamicin (InO) are B-cell targeted agents used in the frontline and relapsed/refractory treatment of B-cell acute lymphoblastic leukaemia (B-ALL). Blinatumomab, a bispecific T-cell engager that targets CD19 and CD3, and InO, an antibody-drug conjugate targeting CD22, have both shown efficacy. However, recent reports have noted lineage conversion as a complication when these agents are used individually or sequentially.

View Article and Find Full Text PDF

Intraosseous Hemangioma of the Zygomatic Bone: A Rare Maxillofacial Case in a 57-Year-Old Woman.

Case Rep Dent

September 2025

Department of Oral and Maxillofacial Radiology, School of Dentistry, Zanjan University of Medical Sciences, Zanjan, Zanjan Province, Iran.

Central hemangioma is one of the rare lesions of the jawbones, with a prevalence ranging between 0.5% and 1%. It more commonly occurs in the vertebral column and cranial bones, with rare occurrences in the jaws.

View Article and Find Full Text PDF

Purpose: Acute graft-versus-host disease (aGVHD) is a significant cause of death in recipients of allogeneic hematopoietic stem cell transplantation. In this type of graft, the intestine is particularly affected, with the loss of intestinal barrier integrity playing a key role in its onset. In this scenario, the aim of the present research was to evaluate defibrotide, a heparin-like compound, marked for severe veno-occlusive disease, as an innovative therapeutic approach for restoring intestinal barrier integrity using an in vitro model and analyzing aGVHD patients' sera and clinical data.

View Article and Find Full Text PDF

Medication-related osteonecrosis of the jaw (MRONJ) is a rare but well-recognized complication of treatment with antiresorptive agents. Medication-related osteonecrosis of the external auditory canal (MROEAC), on the other hand, is even rarer and mostly reported during bisphosphonate exposure. Its pathophysiology is thought to involve complex multifactorial processes, including inhibition of bone remodeling, altered angiogenesis, infection, and inflammation.

View Article and Find Full Text PDF

Objective: People who have experienced stroke are at a high risk for falls, fractures, and osteoporosis. Bone health post-stroke is often overlooked. The goal of this study was to understand current practice perspectives and barriers to bone health care post-stroke among physiatrists.

View Article and Find Full Text PDF